News
MOR
18.14
0.00%
0.00
MorphoSys AG Reports Major Shareholding Changes
TipRanks · 1d ago
MorphoSys AG Reports Major Shareholding Change
TipRanks · 2d ago
MorphoSys AG Reports Major Stake Change
TipRanks · 3d ago
Weekly Report: what happened at MOR last week (0318-0322)?
Weekly Report · 4d ago
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
NASDAQ · 6d ago
MorphoSys AG Reports Major Voting Rights Change
Morphosys AG has announced a significant change in ownership. DWS Investment GmbH now holds over 4% of the company’s voting rights. The total voting rights associated with the shares and instruments now reach 4.11%. MOR stock will cross the threshold on March 18, 2024.
TipRanks · 6d ago
MorphoSys gains after gaining U.S. antitrust approval for sale to Novartis
MorphoSys AG edged up 1% after gaining U.S. Antitrust approval for sale to Novartis. The cancer drugmaker's planned sale toNovartis has cleared all regulatory hurdles. The deal is expected to close in the first half of this year.
Seeking Alpha · 03/22 14:29
MorphoSys Set for Novartis Takeover Post-U.S. Clearance
TipRanks · 03/22 11:27
MorphoSys Bags US Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
MorphoSys AG announced the receipt of U.S. Antitrust clearance in connection with the proposed acquisition of MorphoSys by Novartis AG. The proposed acquisition by Novarts has now received all mandatory regulatory approvals in Germany and Austria. On February 5, 2024, Novarts is expected to submit a voluntary public takeover offer for Morphosys.
Benzinga · 03/22 07:04
MorphoSys Receives U.S. Antitrust Approval For Acquisition By Novartis
NASDAQ · 03/22 06:56
BRIEF-Morphosys Announces U.S. Antitrust Clearance Of Proposed Acquisition By Novartis Under Hart-Scott-Rodino Act
Morphosys Announces U.S. Antitrust Clearance Of Proposed Acquisition By Novartis Under Hart-Scott-Rodino Act. Morphosys expects to close the deal in the first half of 2024. The company says the proposed acquisition has all required regulatory approval.
Reuters · 03/22 06:41
MorphoSys AG Announces Major Voting Rights Changes
TipRanks · 03/21 16:27
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
NASDAQ · 03/21 14:20
MorphoSys’ Milestone Year Paves Way for Growth
TipRanks · 03/20 20:57
MorphoSys AG Announces Shift in Shareholding
TipRanks · 03/20 16:27
MorphoSys AG Reports Major Voting Rights Change
TipRanks · 03/19 15:57
MorphoSys AG Witnesses Major Voting Rights Shift
TipRanks · 03/18 16:27
Weekly Report: what happened at MOR last week (0311-0315)?
Weekly Report · 03/18 09:01
MorphoSys Cut to Equal-Weight From Overweight by Wells Fargo
Dow Jones · 03/14 20:16
MorphoSys Price Target Raised to $18.25/Share From $17.00 by Wells Fargo
Dow Jones · 03/14 20:16
More
Webull provides a variety of real-time MOR stock news. You can receive the latest news about Morphosys Ag through multiple platforms. This information may help you make smarter investment decisions.
About MOR
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.